February 23, 2006 – Genzyme ended early the enrollment of patients into a Phase II trial of its cell therapy, intended to repair damaged hearts; Nastech Pharma acquired the RNAi technology of Galenea Corporation, including IP licensed from MIT; GTC Biotherapeutics saw 40% of its market value disappear after European authorities recommended against approval of ATryn, an anti-clotting drug; Amgen published positive data from a Phase II trial of its osteoporosis drug, denosumab; Replidyne and Forest Labs reported the FDA has accepted their filing for approval of an antibiotic; and Bioenvision received European recommendation for Evoltra, a therapy for acute lymphobloastic leukemia. The Centient Biotech 200™ was 10 points lower at 3959.90, a drop of .25%. More details...
